TPST Latest Report

Performance of This Quarter's Financial Report

Tempest Therapeutics (stock code: TPST) recorded an operating income of -13918000 yuan at the end of 2024, a significant decrease from -7514000 yuan at the end of 2023. The continuous negative income indicates that the company has not achieved profitability in the past two years, and the negative income in 2024 has further exacerbated its financial difficulties.

Key Data in the Financial Report

1. The operating income in 2024 was -13918000 yuan, compared with -7514000 yuan in 2023, indicating a significant increase in losses.

2. R&D expenses in 2024 were RMB 10742000, a significant increase from RMB 4183000 in 2023, which may temporarily suppress operating income.

3. Marketing, sales, and general management expenses in 2024 were RMB 3176000, slightly lower than RMB 3331000 in 2023, but still exerting pressure on income.

4. Intensified external competition may lead to a decrease in product sales.

5. Uncertainty in the macroeconomic environment affects customer purchasing decisions, further leading to a decrease in revenue.

Peer Comparison

1. Industry-wide analysis: In the biopharmaceutical industry, many companies faced similar challenges in 2024, especially with increased R&D spending, which put pressure on short-term operating income. The overall trend suggests that while short-term revenue may decrease, long-term investment may lead to profitability.

2. Peer evaluation analysis: TPST's revenue performance is poor, especially in the context of other companies in the industry improving revenue through operational optimization, TPST failed to effectively convert R&D investment into sales revenue, indicating its competitive disadvantage.

Summary

TPST's operating income has continued to be in the red, and the loss in 2024 has further deepened, mainly due to intensified competition, insufficient product demand, increased R&D investment, and uncertainty in the macroeconomic environment. These factors have collectively affected the company's financial health and future profitability.

Opportunities

1. Actively promote the development of in-process products, especially in the field of cancer treatment, which may lead to revenue growth in the future.

2. Approval of multiple clinical trials demonstrates strong potential in terms of R&D efficiency and market demand.

3. The industry's overall transformation towards high-quality innovation may provide new market opportunities for the company.

4. The application of new digital and decentralized clinical trial technologies may improve R&D efficiency and reduce costs.

Risks

1. Continuous negative income may lead to cash flow shortages, affecting the company's operations and development.

2. A significant increase in R&D expenses may not generate corresponding sales revenue in the short term.

3. Fluctuations in the external economic environment may affect market demand, especially for non-essential products.

4. Intensified competition will continue to exert pressure on the company's revenue, leading to a further decline in market share.